JP2020520917A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520917A5
JP2020520917A5 JP2019563463A JP2019563463A JP2020520917A5 JP 2020520917 A5 JP2020520917 A5 JP 2020520917A5 JP 2019563463 A JP2019563463 A JP 2019563463A JP 2019563463 A JP2019563463 A JP 2019563463A JP 2020520917 A5 JP2020520917 A5 JP 2020520917A5
Authority
JP
Japan
Prior art keywords
positively charged
gly
botulinum toxin
pharmaceutical composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033397 external-priority patent/WO2018213710A1/en
Publication of JP2020520917A publication Critical patent/JP2020520917A/ja
Publication of JP2020520917A5 publication Critical patent/JP2020520917A5/ja
Pending legal-status Critical Current

Links

JP2019563463A 2017-05-18 2018-05-18 頸部ジストニアの治療方法 Pending JP2020520917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508324P 2017-05-18 2017-05-18
US62/508,324 2017-05-18
PCT/US2018/033397 WO2018213710A1 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia

Publications (2)

Publication Number Publication Date
JP2020520917A JP2020520917A (ja) 2020-07-16
JP2020520917A5 true JP2020520917A5 (https=) 2021-07-26

Family

ID=64274745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563463A Pending JP2020520917A (ja) 2017-05-18 2018-05-18 頸部ジストニアの治療方法

Country Status (13)

Country Link
US (3) US20200179498A1 (https=)
EP (1) EP3624819A4 (https=)
JP (1) JP2020520917A (https=)
KR (2) KR102777928B1 (https=)
CN (1) CN110996979A (https=)
AU (2) AU2018270092C1 (https=)
BR (1) BR112019024082A2 (https=)
CA (1) CA3064070A1 (https=)
CO (1) CO2019014212A2 (https=)
MX (1) MX2019013716A (https=)
PH (1) PH12019502578A1 (https=)
RU (1) RU2019141383A (https=)
WO (1) WO2018213710A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20230086752A (ko) * 2020-10-13 2023-06-15 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
US20250268996A1 (en) * 2021-02-21 2025-08-28 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
AU2024342863A1 (en) 2023-09-15 2026-04-09 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
AU2009332947C1 (en) * 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) * 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US8147848B2 (en) * 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
PT2661276T (pt) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
SG11202005239YA (en) 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
RU2741221C1 (ru) 2020-04-30 2021-01-22 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом

Similar Documents

Publication Publication Date Title
JP2020520917A5 (https=)
JP2019194251A5 (https=)
RU2018118651A (ru) Композиции и способы терапии, связанной с фекальной микробиотой
JP2012532185A5 (https=)
HRP20191852T1 (hr) Polipeptidi
JP2015517488A5 (https=)
RU2013108248A (ru) Иммуногенные противовоспалительные композиции
RU2020121540A (ru) Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
JP2019520841A5 (https=)
JP2017523985A5 (https=)
JP2015518818A5 (https=)
CY1115841T1 (el) Εμβολια πεπτιδιου παραγομενα απο epha4
JP2012176978A5 (https=)
JP2014502628A5 (https=)
JP2013509389A5 (https=)
JP2018502956A5 (https=)
JP2015529685A5 (https=)
JP2016518442A5 (https=)
JP2015510393A5 (https=)
FI3065763T4 (fi) Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten
RU2019141383A (ru) Способы лечения цервикальной дистонии
JP2017512194A5 (https=)
RU2015106742A (ru) Композиции, содержащие химерные молекулы ospa и способы их применения
Lin et al. Antimicrobial peptide-inspired antibacterial polymeric materials for biosafety
JP2020117504A5 (https=)